Stocktoria
Onconetix, Inc. ONCO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-02-18
Onconetix, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 77.6% | 41.8% | -1927.9% | — | — |
| Operating margin | -2190.0% | -2238.0% | -61634.5% | — | — |
| Net margin | -1721.0% | -2325.2% | -63986.5% | — | — |
| FCF margin | — | -416.9% | -23235.0% | — | — |
| Return on assets | -56.3% | -208.3% | -42.7% | -51.0% | -110.8% |
| Return on equity | -89.0% | -687.0% | 667.8% | -59.9% | -236.2% |
| Current ratio | 0.66 | 0.05 | 0.34 | 6.69 | 1.88 |
| Revenue growth | -67.7% | 4217.3% | — | — | — |
Source: SEC EDGAR filings · CIK 0001782107 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.